Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
The live webcast of the presentation will be available on the Investors page of the Company's website, https://ir.merus.nl. An archived presentation will be available on the Merus website for a limited time.
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, http://www.merus.nl and https://twitter.com/MerusNV.
Investor and Media Inquiries:
Jillian ConnellMerus N.V. Investor Relations and Corporate Communications 617-955-4716 email@example.com Kathleen FarrenMerus N.V. Communications Specialist 617-230-4165 firstname.lastname@example.org